HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In Brief: Alberto/St. Ives buy

This article was originally published in The Rose Sheet

Executive Summary

Alberto/St. Ives buy: Alberto-Culver completes its acquisition of St. Ives Labs for $120 mil. in cash, or $15 a share, Feb. 6. The purchase, which was announced Oct. 31 ("The Rose Sheet" Nov. 6, p. 1), bolsters Alberto's sales by about 12% -- Alberto posted net sales of $1.35 bil. in FY 1995 (ended Sept. 30), while St. Ives revenues totalled $160 mil. in 1995. The acquisition adds St. Ives Swiss Formula skin and hair care brands to Alberto's hair care line-up, which includes the Alberto VO5 franchise and the TRESemme brand. Alberto projected that the merger would be non-dilutive to the firm's 1996 earnings and accretive to earnings in following years...

Alberto/St. Ives buy: Alberto-Culver completes its acquisition of St. Ives Labs for $120 mil. in cash, or $15 a share, Feb. 6. The purchase, which was announced Oct. 31 ("The Rose Sheet" Nov. 6, p. 1), bolsters Alberto's sales by about 12% -- Alberto posted net sales of $1.35 bil. in FY 1995 (ended Sept. 30), while St. Ives revenues totalled $160 mil. in 1995. The acquisition adds St. Ives Swiss Formula skin and hair care brands to Alberto's hair care line-up, which includes the Alberto VO5 franchise and the TRESemme brand. Alberto projected that the merger would be non-dilutive to the firm's 1996 earnings and accretive to earnings in following years....

Latest Headlines
See All
UsernamePublicRestriction

Register

RS002478

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel